Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43691   clinical trials with a EudraCT protocol, of which   7245   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43,691 result(s) found. Displaying page 1,786 of 2,185.
    EudraCT Number: 2011-002667-14 Sponsor Protocol Number: UHKT-RLP/2011 Start Date*: 2011-07-19
    Sponsor Name:Institute of Hematology and Blood Transfusion
    Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?
    Medical condition: Recurrent respiratory papillomatosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023849 Laryngeal papilloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-002560-10 Sponsor Protocol Number: NOA-07 Start Date*: 2008-11-04
    Sponsor Name:Freistaat Bayern, represented by the University of Regensburg
    Full Title: Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07)
    Medical condition: Therapy of medulloblastoma of adults
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000901-19 Sponsor Protocol Number: PSA‐PI‐006421 Start Date*: 2017-09-11
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
    Full Title: Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis.
    Medical condition: Psoriasic arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-002114-38 Sponsor Protocol Number: KSL0118 Start Date*: 2019-09-04
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Randomized, single dose, placebo-controlled, double-blind, parallel group study to evaluate the onset of pain response after administration of ketoprofen lysine salt 40 mg, in male and female subje...
    Medical condition: pain management in odontoiatry
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10062132 Tooth extraction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002248-98 Sponsor Protocol Number: TN-10 Start Date*: 2016-01-15
    Sponsor Name:TrialNet Coordinating Center
    Full Title: Anti-CD3 mAb (teplizumab) for prevention of diabetes in relatives at-risk for Type 1 diabetes mellitus
    Medical condition: Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004914-79 Sponsor Protocol Number: CA017-003 Start Date*: 2016-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed) FI (Completed) SE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-001677-28 Sponsor Protocol Number: 2007/08 Start Date*: 2007-11-28
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Quantification of the anesthetic effect of nitrous oxide using intravenous "closed-loop" anesthesia
    Medical condition: This is a study of the anesthetic effect of the IMP, nitrous oxide. In this sense "general anesthesia" can be termed the medical condition under investigation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003662-27 Sponsor Protocol Number: CA209-9X8 Start Date*: 2018-04-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014444-11 Sponsor Protocol Number: RET04.09 Start Date*: 2009-08-10
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038901 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005002-30 Sponsor Protocol Number: ICORG09-13 Start Date*: 2012-01-05
    Sponsor Name:ICORG-the All Ireland co-operative Oncology Research group
    Full Title: Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.
    Medical condition: Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002066-32 Sponsor Protocol Number: BEB-13 Start Date*: 2017-11-10
    Sponsor Name:Amryt Research Limited
    Full Title: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa
    Medical condition: Inherited Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) DE (Completed) ES (Ongoing) GR (Completed) HU (Completed) CZ (Completed) BE (Completed) DK (Completed) IT (Ongoing) HR (Completed) FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001510-15 Sponsor Protocol Number: CNTO1959UCO2002 Start Date*: 2019-05-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and G...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005068-13 Sponsor Protocol Number: I4T-MC-JVDE Start Date*: 2015-08-07
    Sponsor Name:Eli Lilly and Company
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma a...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) PL (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001179-36 Sponsor Protocol Number: RHB-104-01 Start Date*: 2015-07-24
    Sponsor Name:RedHill Biopharma Ltd.
    Full Title: A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severe...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-014912-36 Sponsor Protocol Number: SIM001 Start Date*: 2009-09-22
    Sponsor Name:Karolinska Institutet
    Full Title: Behandling vid Langerhans cellhistiocytos (LCH)
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005637-38 Sponsor Protocol Number: TREnd_trial Start Date*: 2012-09-07
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS
    Full Title: PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN...
    Medical condition: ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002140-27 Sponsor Protocol Number: 112909 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pne...
    Medical condition: Healthy volunteers (Vaccination against Streptococcus pneumoniae in healthy children previously enrolled in study 10PN-PD-DIT-037 (111188).)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003984-20 Sponsor Protocol Number: LSK-AM301 Start Date*: 2017-12-11
    Sponsor Name:Elevar Therapeutics, Inc
    Full Title: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care ...
    Medical condition: Advanced or Metastatic Gastric Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-000445-19 Sponsor Protocol Number: SAKK 17/04 Start Date*: 2007-07-27
    Sponsor Name:Swiss group for clinical cancer research
    Full Title: Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial
    Medical condition: Patients with pleural mesothelioma, T<=3, N<=2, M0 (IMIG-system)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035603 Pleural mesothelioma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003798-82 Sponsor Protocol Number: R1578 Start Date*: 2014-01-29
    Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust
    Full Title: Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease; The STOP-ACEi Trial
    Medical condition: Progressive, advanced (stage 4 or 5) chronic kidney disease (CKD). NB. There was not an appropriate therapeutic area in the drop down menu in E1-1. Have selected 'Male diseases of the urinary and...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA